AU2007307157A1 - Effective delivery of cross-species A3 adenosine-receptor antagonists to reduce intraocular pressure - Google Patents

Effective delivery of cross-species A3 adenosine-receptor antagonists to reduce intraocular pressure Download PDF

Info

Publication number
AU2007307157A1
AU2007307157A1 AU2007307157A AU2007307157A AU2007307157A1 AU 2007307157 A1 AU2007307157 A1 AU 2007307157A1 AU 2007307157 A AU2007307157 A AU 2007307157A AU 2007307157 A AU2007307157 A AU 2007307157A AU 2007307157 A1 AU2007307157 A1 AU 2007307157A1
Authority
AU
Australia
Prior art keywords
mrs
intraocular pressure
eye
iop
adenosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007307157A
Other languages
English (en)
Inventor
Marcel Y. Avila
Mortimer M. Civan
Kenneth A. Jacobson
Richard Stone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania
Original Assignee
University of Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania filed Critical University of Pennsylvania
Publication of AU2007307157A1 publication Critical patent/AU2007307157A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AU2007307157A 2006-10-06 2007-10-05 Effective delivery of cross-species A3 adenosine-receptor antagonists to reduce intraocular pressure Abandoned AU2007307157A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85017506P 2006-10-06 2006-10-06
US60/850,175 2006-10-06
PCT/US2007/021409 WO2008045330A2 (en) 2006-10-06 2007-10-05 Effective delivery of cross-species a3 adenosine-receptor antagonists to reduce intraocular pressure

Publications (1)

Publication Number Publication Date
AU2007307157A1 true AU2007307157A1 (en) 2008-04-17

Family

ID=39283379

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007307157A Abandoned AU2007307157A1 (en) 2006-10-06 2007-10-05 Effective delivery of cross-species A3 adenosine-receptor antagonists to reduce intraocular pressure

Country Status (8)

Country Link
US (1) US20090258836A1 (cg-RX-API-DMAC7.html)
EP (1) EP2076267A4 (cg-RX-API-DMAC7.html)
JP (1) JP2010505848A (cg-RX-API-DMAC7.html)
AU (1) AU2007307157A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0715318A2 (cg-RX-API-DMAC7.html)
CA (1) CA2665616A1 (cg-RX-API-DMAC7.html)
MX (1) MX2009003750A (cg-RX-API-DMAC7.html)
WO (1) WO2008045330A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013516495A (ja) 2010-01-11 2013-05-13 イノテック ファーマシューティカルズ コーポレイション 眼圧を低下させる組合せ、キット、および方法
JP2013523739A (ja) * 2010-03-26 2013-06-17 イノテック ファーマシューティカルズ コーポレイション N6−シクロペンチルアデノシン(cpa)、cpa誘導体またはそれらのプロドラッグを用いてヒトにおける眼内圧を低下させる方法
SMT201700377T1 (it) 2012-01-26 2017-09-07 Inotek Pharmaceuticals Corp Polimorfi anidri di (2r,3s,4r,5r)-5-(6-(ciclopentilammino)-9h-purin-9-il)-3,4- diidrossitetraidrofuran-2-il)}metil nitrato e processi di sua preparazione
NZ630759A (en) 2013-03-15 2017-07-28 Inotek Pharmaceuticals Corp Ophthalmic formulations comprising an a1 agonist
ES2578363B1 (es) 2015-01-22 2017-01-31 Palobiofarma, S.L. Moduladores de los receptores A3 de adenosina
US10196396B2 (en) 2016-01-14 2019-02-05 Handok Inc. Compounds antagonizing A3 adenosine receptor, method for preparing them, and medical-use thereof
ES2676535B1 (es) 2017-01-20 2019-04-29 Palobiofarma Sl Moduladores de los receptores a3 de adenosina
KR101805400B1 (ko) * 2017-03-21 2017-12-07 퓨쳐메디신 주식회사 아데노신 유도체를 포함하는 녹내장 예방 및 치료용 약학적 조성물
CN109666053A (zh) * 2017-10-16 2019-04-23 张家口华健致远生物科技有限公司 一种a3腺苷受体激动剂及其用途
KR102007640B1 (ko) * 2017-11-29 2019-08-07 퓨쳐메디신 주식회사 아데노신 유도체를 포함하는 망막 질환 또는 시신경 질환 예방 및 치료용 약학적 조성물
US11395597B2 (en) * 2018-06-26 2022-07-26 General Electric Company System and method for evaluating blood flow in a vessel

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4431638B2 (ja) * 1996-01-29 2010-03-17 アメリカ合衆国 ジヒドロピリジン―、ピリジン―、ベンゾピラン―オン―およびトリアゾロキナゾリン誘導体、それらの製造およびそれらのアデノシン受容体アンタゴニストとしての用途
EP1096975B1 (en) * 1998-07-16 2005-03-16 The Trustees Of The University Of Pennsylvania Use of a3 adenosine receptor antagonists in the manufacture of a medicament for reducing intraocular pressure
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist

Also Published As

Publication number Publication date
BRPI0715318A2 (pt) 2013-07-16
EP2076267A4 (en) 2013-07-31
US20090258836A1 (en) 2009-10-15
WO2008045330A2 (en) 2008-04-17
MX2009003750A (es) 2009-06-18
JP2010505848A (ja) 2010-02-25
EP2076267A2 (en) 2009-07-08
WO2008045330A3 (en) 2008-06-26
CA2665616A1 (en) 2008-04-17

Similar Documents

Publication Publication Date Title
US20090258836A1 (en) Effective delivery of cross-species a3 adenosine-receptor antagonists to reduce intraocular pressure
US6528516B1 (en) Methods for reducing intraocular pressure using A3 adenosine receptor antagonists
Kent et al. Vitreous concentration of topically applied brimonidine tartrate 0.2%
Koseki et al. A placebo-controlled 3-year study of a calcium blocker on visual field and ocular circulation in glaucoma with low-normal pressure
Guha et al. Lysosomal alkalinization, lipid oxidation, and reduced phagosome clearance triggered by activation of the P2X7 receptor
Nuyen et al. Steroid-induced glaucoma in the pediatric population
Uckermann et al. The glucocorticoid triamcinolone acetonide inhibits osmotic swelling of retinal glial cells via stimulation of endogenous adenosine signaling
Levy et al. Ocular hypotensive safety and systemic absorption of AR-13324 ophthalmic solution in normal volunteers
Kapin et al. Inflammation-mediated retinal edema in the rabbit is inhibited by topical nepafenac
Sigurdsson et al. Cyclodextrin formulation of dorzolamide and its distribution in the eye after topical administration
Wang et al. Nucleoside-derived antagonists to A3 adenosine receptors lower mouse intraocular pressure and act across species
US12102640B2 (en) Use of dopamine and serotonin receptor antagonists for treatment in a subject with retinal degeneration
WO2018009717A1 (en) Trpa1 antagonists for treatment of dry eye, ocular pain and inflammation
Chien et al. Ocular pharmacokinetics and pharmacodynamics of phenylephrine and phenylephrine oxazolidine in rabbit eyes
Brubaker et al. Topical forskolin (colforsin) and aqueous flow in humans
JP7816716B2 (ja) 強膜菲薄化治療用点眼剤及び強膜菲薄化治療剤のスクリーニング方法
Sponsel et al. Periocular accumulation of timolol and betaxolol in glaucoma patients under long-term therapy
KR20180094879A (ko) 망막 질환을 치료하기 위한 미라베그론
Wang et al. Barrier qualities of the mouse eye to topically applied drugs
US20090054412A1 (en) Treatment of Sleep Disorders
US10370378B2 (en) Treatment of sleep disorders
Schoenwald et al. The ocular pharmacokinetics of ketanserin and its metabolite, ketanserinol, in albino rabbits
Konno et al. Effect of 2-(6-cyano-1-hexyn-1-yl) adenosine on ocular blood flow in rabbits
Manzoni et al. P-9-1 Effect of ceftriaxone, gabapentin and lamotrigine on [3H] glutamate uptake in an animal model of amyotrophic lateral sclerosis
WO2006138487A2 (en) Treatment of ischemia-induced arrhythmias

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE CO-INVENTOR NAME FROM MOR- TIMER, CIVAN M. TO CIVAN, MORTIMER M.

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application